CARLSBAD, Calif. (BUSINESS WIRE) $LCTX #LineageCellTherapeutics Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it entered into a definitive agreement with certain investors fo.
Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX – Get Free Report) was the target of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 7,880,000 shares, a growth of 13.5% from the December 31st total of 6,940,000 shares. Based on an average daily trading volume, of […]
/PRNewswire/ The hematopoietic stem cells transplantation (HSCT) market size is estimated to increase by USD 2.38 billion from 2023 to 2027, with a CAGR of.
Spinal Cord Injury Therapeutics Market surpass $10 7 billion by 2031 - Exclusive Report by Coherent Market Insights finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.